Clinical trials: Monoclonal
Glioblastoma Multiforme
Dose Confirmation Study of Cotara for the Treatment of Glioblastoma Multiforme at First Relapse
Cotara® is an experimental new treatment that links a radioactive isotope (iodine 131) to a targeted monoclonal antibody. This monoclonal antibody is designed to bind tumor cells and deliver radiation directly to the center of…
- Trial name
- NCT00677716
- Testing
- 131I-chTNT-1/B MAb (Cotara)
- Where
- 7 sites in United States, India
- Volunteers
- 41 people
- Sponsor
- Peregrine Pharmaceuticals
Rh Disease
Pharmacokinetics and Safety of Roledumab in RhD-negative Pregnant Women Carrying an RhD-positive Foetus
The aim of this study is to assess the pharmacokinetic profile of Roledumab 300μg IM / IV in RhD-negative pregnant women carrying an RhD-positive foetus.
- Trial name
- NCT02287896
- Testing
- ROLEDUMAB
- Where
- 8 sites in France
- Volunteers
- 62 people
- Sponsor
- Laboratoire français de Fractionnement et de Biotechnologies
Relapsed or Refractory Multiple Myeloma
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to compare the efficacy of teclistamab with PVd/Kd in Part 1 and to further characterize safety and efficacy of an alternative dosing for teclistamab in Part 2 in participants with relapsed or…
- Trial name
- MajesTEC-9 (NCT05572515)
- Testing
- Teclistamab, Pomalidomide, Bortezomib
- Where
- 211 sites in United States, Australia and 22 more
- Volunteers
- 614 people
- Sponsor
- Janssen Research & Development, LLC
Gastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ)
HLX07+HLX10+Chemotherapy or HLX07 Monotherapy in Patients With Advanced Metastatic Gastric Cancer
This study is conducted in patients with advanced metastatic gastric cancer including gastroesophageal junction cancer. This study includes two arms: A and B.
- Trial name
- NCT05246982
- Testing
- HLX07+HLX10+oxaliplatin+capecitabine, HLX07
- Where
- 2 sites in China
- Volunteers
- 40 people
- Sponsor
- Shanghai Henlius Biotech
Crohn's Disease
Efficacy, Safety and Tolerability of AIN457 in Moderate to Severe Active Crohn's Disease
This study will assess the safety and efficacy of AIN457 in patients with moderate to severe active Crohn's disease.
- Trial name
- NCT00584740
- Testing
- AIN457
- Where
- 2 sites in Germany
- Volunteers
- 59 people
- Sponsor
- Novartis Pharmaceuticals
MSI-H/dMMR Solid Tumors
Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors
In this Phase 2, Single-Arm, Multi-Center, Open-Label Study, participants with previously treated locally advanced unresectable or metastatic solid tumors with mismatched repair deficient (dMMR) or microsatellite instability-high…
- Trial name
- NCT03736889
- Testing
- Tislelizumab (BGB-A317)
- Where
- 29 sites in China
- Volunteers
- 200 people
- Sponsor
- BeiGene
High-grade Osteosarcoma
Study of ZKAB001 for Maintenance Therapy in Patients With High-grade Osteosarcoma After Adjuvant Chemotherapy
It is a randomized, double-blind, placebo-controlled, multicenter study with the sample size is 362. The patients with high-grade osteosarcoma who had previously received surgery and completed adjuvant chemotherapy will be…
- Trial name
- NCT04359550
- Testing
- Recombinant human anti-PD-L1 monoclonal antibody (ZKAB001)
- Volunteers
- 362 people
- Sponsor
- Lee's Pharmaceutical Limited
Solid Tumors
Study of IMC-11F8 in Patients With Tumors Who Have Not Responded to Standard Therapy
The purpose of this study is to determine if IMC-11F8 is safe for patients, and also to determine the best dose of IMC-11F8 to give to patients.
- Trial name
- NCT00801177
- Testing
- IMC-11F8, IMC-11F8 I.V.
- Where
- 2 sites in Netherlands
- Volunteers
- 60 people
- Sponsor
- Eli Lilly and Company
Asthma
A Study to Evaluate the Pharmacokinetics of Tezepelumab After Being Delivered by an Accessorized Pre Filled Syringe or Autoinjector Compared With Vial and Syringe in Healthy Adult Subjects
This is a study to compare PK of tezepelumab exposure in healthy subjects by using vial and syringe, APFS, and AI.
- Trial name
- PATH-BRIDGE (NCT03989544)
- Testing
- Tezepelumab
- Where
- Germany
- Volunteers
- 315 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Solid Tumor
First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.
The purpose of this study is to determine the safety, blood concentrations and treatment effect of CRB-601 in combination with immunotherapy in patients who have advanced solid tumors (cancer) and have exhausted other therapeutic…
- Trial name
- NCT06603844
- Testing
- CRB-601 monoclonal antibody, Anti-PD-1 monoclonal antibody
- Where
- 26 sites in United States, United Kingdom
- Volunteers
- 156 people
- Sponsor
- Corbus Pharmaceuticals Inc.
Communicable Disease Transmission, Zoonotic Disease
A Bridging Study of the SYN023 on Healthy Adult Subjects
The Phase I bridging clinical trial is to evaluate on the safety, pharmacokinetics (PK), pharmacodynamics (PD) and ADA of a single intramuscular injection of recombinant anti-rabies human monoclonal antibody injection (SYN023)…
- Conditions
- Communicable Disease Transmission, Zoonotic Disease, Rabies Human, Vaccine Reaction
- Trial name
- NCT04495569
- Testing
- recombinant anti-rabies human monoclonal antibody injection (SYN023), Rabies Vaccine
- Where
- China
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Synermore Biologics (Suzhou) Co., Ltd.
Acute Gout
Targeted Dose Finding of Canakinumab (ACZ885) for Management of Acute Flare in Refractory or Contraindicated Gout Patients
This 8-week study is designed to determine the target dose of canakinumab (ACZ885) for the management of acute flare in gout patients who are contraindicated to Non-Steroidal anti-inflammatory drugs and/or colchicine.
- Trial name
- NCT00798369
- Testing
- Canakinumab, Triamcinolone acetonide
- Where
- 75 sites in United States, Argentina and 9 more
- Volunteers
- 200 people
- Sponsor
- Novartis
Diabetes Mellitus, Type 1
Recent-Onset Type 1 Diabetes Extension Study Evaluating the Long-Term Safety of Teplizumab (PROTECT Extension)
The purpose of this non-interventional extension study is to continue to collect long-term safety and other clinical data for an additional 42 months in participants who completed the PROTECT study.
- Trial name
- NCT04598893
- Testing
- Teplizumab
- Where
- 47 sites in United States, Belgium and 6 more
- Volunteers
- 188 people
- Sponsor
- Provention Bio, a Sanofi Company
Non Small Cell Lung Cancer (NSCLC)
Study of Cisplatin/Vinorelbine +/- Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer (FLEX)
The purpose of this trial is to investigate the efficacy of cetuximab in combination with chemotherapy in comparison to chemotherapy alone in patients with advanced non small cell lung cancer who did not received prior…
- Trial name
- FLEX (NCT00148798)
- Testing
- cetuximab + cisplatin + vinorelbine, cisplatin + vinorelbine
- Where
- 118 sites in Argentina, Australia and 26 more
- Volunteers
- 1,861 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Advanced Solid Tumor, Metastatic Solid Tumor
BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors
This study aims to evaluate how safe and well-tolerated the treatment is, how the body processes it, how it works on the tumors, and whether it shows early signs of fighting cancer in people with certain advanced or metastatic…
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Solid Tumor
- Trial name
- NCT05935098
- Testing
- BGB-A3055, Tislelizumab, Chemotherapy
- Where
- 26 sites in United States, Australia and 3 more
- Volunteers
- 99 people
- Sponsor
- BeiGene
Healthy Volunteers
Adrecizumab-LPS Study
In this randomized, double-blind, placebo-controlled study, either a single dose of Adrecizumab (0.5, 2.0 or 8.0 mg/kg) or placebo will be administrated to 24 healthy male volunteers during experimental endotoxemia.
- Trial name
- NCT03083171
- Testing
- Endotoxin, Adrecizumab
- Where
- Netherlands
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Adrenomed AG
Malignant Melanoma
An Open-Label, Dose-Escalation Study of IMC-20D7S In Participants With Malignant Melanoma
A dose-escalation study designed to determine the safety, maximum tolerated dose (MTD), anti-melanoma activity, antibody blood levels and progression-free survival (PFS) in participants with malignant melanoma receiving IMC-20D7S…
- Trial name
- NCT01137006
- Testing
- IMC-20D7S (Cohort 1A), IMC-20D7S (Cohort 2A), IMC-20D7S (Cohort 3A)
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- Eli Lilly and Company
Healthy
A Study to Evaluate Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Multiple Doses of VIS954
The purpose of this study is to evaluate the safety, pharmacokinetics, and pharmacodynamics of multiple doses of VIS954 compared with placebo in healthy adult participants.
- Trial name
- NCT06937593
- Testing
- VIS954
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Staphylococcal Sepsis
Safety and Efficacy of Pagibaximab Injection in Very Low Birth Weight Neonates for Prevention of Staphylococcal Sepsis
Evaluate the safety, PK and efficacy comparing Pagibaximab Injection to placebo in preventing staphylococcal sepsis in very low birth weight infants.
- Trial name
- NCT00646399
- Testing
- Pagibaximab 50 mg/mL
- Where
- United States
- Volunteers
- 1,579 people, healthy volunteers welcome
- Sponsor
- Biosynexus Incorporated
Advanced Malignancies
A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-cluster Differentiation Antigen 47 (CD47) Monoclonal Antibody Injection (IBI188) in Patients With Advanced Malignant Tumors and Lymphomas
This is an open-label, dose escalation, Phase I study to evaluate the safety, tolerability, pharmacokinetics and efficacy in patients with advanced malignancies.
- Trial name
- NCT03763149
- Testing
- IBI188
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.